Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with P
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q4 2023 | POLYETHYLENE GLYCOL 300 | INTRAVENOUS | INJECTION, SOLUTION, CONCENTRATE | 3582mg | Correction | ||
| Q1 2024 | POLYETHYLENE GLYCOL 300 | INTRAVENOUS | INJECTION, SOLUTION, CONCENTRATE | 358mg | Correction | ||
| Q4 2023 | PROPYLENE GLYCOL | OPHTHALMIC | SUSPENSION/ DROPS | 1.00 %v/v | Correction | ||
| Q1 2024 | PROPYLENE GLYCOL | OPHTHALMIC | SUSPENSION/ DROPS | 0.75 %w/v | Correction | ||
| Q1 2024 | POLOXAMER 407 | TOPICAL | SOLUTION | 0.20 %w/w | Deletion | ||
| Q1 2024 | POLYCARBOPHIL | TOPICAL | SOLUTION | 0.88 %w/w | Deletion | ||
| Q1 2024 | POLYETHYLENE GLYCOL 3350 | INTRALESIONAL | INJECTION | 2.91 %w/v | 56mg | Deletion | |
| Q1 2024 | POLYETHYLENE GLYCOL 3350 | SOFT TISSUE | INJECTION | 2.91 %w/v | 56mg | Deletion | |
| Q4 2023 | PARAFFIN | TOPICAL | OINTMENT | 69.00 %w/w | MDE Replacement | ||
| Q1 2024 | PARAFFIN | TOPICAL | OINTMENT | 1800mg | MDE Replacement | ||
| Q4 2023 | POLYETHYLENE GLYCOL 3350 | INTRASYNOVIAL | INJECTION, SUSPENSION | 2.91 %w/v | MDE Replacement | ||
| Q1 2024 | POLYETHYLENE GLYCOL 3350 | INTRASYNOVIAL | INJECTION, SUSPENSION | 56mg | MDE Replacement | ||
| Q4 2023 | POLYSORBATE 20 | INTRAMUSCULAR | SUSPENSION, EXTENDED RELEASE | 2.00 %w/v | MDE Replacement | ||
| Q1 2024 | POLYSORBATE 20 | INTRAMUSCULAR | SUSPENSION, EXTENDED RELEASE | 60mg | MDE Replacement | ||
| Q4 2023 | POLYSORBATE 80 | INTRASYNOVIAL | INJECTION, SUSPENSION | 0.19 %w/v | MDE Replacement | ||
| Q1 2024 | POLYSORBATE 80 | INTRASYNOVIAL | INJECTION, SUSPENSION | 4mg | MDE Replacement | ||
| Q4 2023 | POTASSIUM HYDROXIDE | TOPICAL | GEL | 0.50 %w/w | MDE Replacement | ||
| Q1 2024 | POTASSIUM HYDROXIDE | TOPICAL | GEL | 3mg | MDE Replacement | ||
| Q4 2023 | PROPYLENE CARBONATE | TOPICAL | OINTMENT | 5.00 %w/w | MDE Replacement | ||
| Q1 2024 | PROPYLENE CARBONATE | TOPICAL | OINTMENT | 3000mg | MDE Replacement | ||
| Q4 2023 | PROPYLPARABEN | SUBCUTANEOUS | INJECTION | 0.20 %w/v | MDE Replacement | ||
| Q1 2024 | PROPYLPARABEN | SUBCUTANEOUS | INJECTION | 2mg | MDE Replacement | ||
| Q4 2023 | PROSOLV SMCC 90 | ORAL | TABLET, CHEWABLE | 28.40 mg | MDE Replacement | ||
| Q1 2024 | PROSOLV SMCC 90 | ORAL | TABLET, CHEWABLE | 28mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: January 5, 2024
Database Last Updated: January 26, 2024